prikaz prve stranice dokumenta Anti-IgE terapija astme i alergijskog rinitisa omalizumabom
  Download
PDF 118.34 KB
Other - Other
Anti-IgE terapija astme i alergijskog rinitisa omalizumabom
Acta Pharmaceutica, 55 (2005), 2; 123-138. urn:nbn:hr:163:360976
Dodig, Slavica; Richter, Darko; Cepelak, Ivana; Benko, Bojan

Institutional repository: Repository of Faculty of Pharmacy and Biochemistry University of Zagreb

Cite this document

Dodig, S., Richter, D., Cepelak, I. & Benko, B. (2005). Anti-IgE terapija astme i alergijskog rinitisa omalizumabom. Acta Pharmaceutica, 55. (2), 123-138. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:360976

Dodig, Slavica, et al. "Anti-IgE terapija astme i alergijskog rinitisa omalizumabom." Acta Pharmaceutica, vol. 55, no. 2, 2005, pp. 123-138. https://urn.nsk.hr/urn:nbn:hr:163:360976

Dodig, Slavica, Darko Richter, Ivana Cepelak and Bojan Benko. "Anti-IgE terapija astme i alergijskog rinitisa omalizumabom." Acta Pharmaceutica 55, no. 2 (2005): 123-138. https://urn.nsk.hr/urn:nbn:hr:163:360976

Dodig, S., et al. (2005) 'Anti-IgE terapija astme i alergijskog rinitisa omalizumabom', Acta Pharmaceutica, 55(2), pp. 123-138. Available at: https://urn.nsk.hr/urn:nbn:hr:163:360976 (Accessed 23 December 2024)

Dodig S, Richter D, Cepelak I, Benko B. Anti-IgE terapija astme i alergijskog rinitisa omalizumabom. Acta Pharmaceutica [Internet]. 2005 [cited 2024 December 23];55(2):123-138. Available at: https://urn.nsk.hr/urn:nbn:hr:163:360976

S. Dodig, D. Richter, I. Cepelak and B. Benko, "Anti-IgE terapija astme i alergijskog rinitisa omalizumabom", Acta Pharmaceutica, vol. 55, no. 2, pp. 123-138, 2005. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:163:360976. [Accessed: 23 December 2024]

Metadata
Title (croatian)Anti-IgE terapija astme i alergijskog rinitisa omalizumabom
Title (english)Anti-IgE therapy with omalizumab in asthma and allergic rhinitis
AuthorSlavica Dodig
AuthorDarko Richter
AuthorIvana Cepelak
AuthorBojan Benko
Author's institutionUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Department of medical biochemistry and haematology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Medical Biochemistry
Abstract (croatian)
Opisani su farmakologija, djelotvornost, doziranje, nuspojave i ekonomičnost primjene anti IgE antitijela – omalizumab. Omalizumab je generičko ime za ljudsko / mišje kimerično (rekombinantno humanizirano) monoklonalno IgG antitijelo. Anti-IgE sprječava vezanje IgE na efektorske stanice i sprječava upalni odgovor posredovan s IgE. Nakon subkutane primjene sporo se apsorbira te dostiže vršnu koncentraciju u serumu nakon 7 do 8 dana. Uz preporučene doze koncentracija slobodnog IgE u serumu smanjuje se unutar jednog sata. Doziranje se podešava prema tjelesnoj masi i koncentraciji IgE-a u serumu. Omalizumab je djelotvoran kao dopunska terapija u pacijenata (starijih od 12 godina) sa slabo kontroliranom umjerenom do teškom alergijskom astmom odnosno s alergijskim rinitisom. Smanjuje potrebu za inhalacijskim kortikosteroidima te pogoršanje astme. Dobro se podnosi, ali sigurnost primjene, kako u odraslih tako i u djece, treba još ispitati.
Abstract (english)
The pharmacology, efficacy, dosage, adverse effects, and economics of anti IgE (omalizumab) are discussed. Omalizumab is the generic name for the human/murine chimeric (recombinant humanized) monoclonal IgG antibody. Anti-IgE prevents IgE from attaching to effector cells, and thereby blunts IgE-mediated inflammatory responses. After subcutaneous administration its absorption is slow, reaching peak concentration in serum after an average of 7-8 days. At recommended doses, serum free IgE levels decrease within 1 hour following the first dose and maintained between doses. Dose and dosing frequency are adjusted according to body mass and serum total IgE concentration before the start of treatment. Omalizumab administered subcutaneously is an effective treatment for add-on therapy in patients with poorly controlled, moderate-to-severe allergic asthma and allergic rhinitis (adults and adolescents >12 years). It reduces the requirement for inhaled corticosteroids while protecting against disease exacerbation. Omalizumab is well tolerated, but the safety profile requires long-term assessment in adults as well as in children.
Keywords (croatian)
Keywords (english)
Languagecroatian
Languageenglish
Publication typeOther - Other
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleActa Pharmaceutica
Numberingvol. 55, no. 2, pp. 123-138
p-ISSN1330-0075
e-ISSN1846-9558
URN:NBNurn:nbn:hr:163:360976
Publication2005
Document URLhttps://hrcak.srce.hr/16751
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2020-04-08 15:03:19